Search results
Showing results for
An individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.
Chris Paton
BMBS BMedSci MBA DPhil FBCS Chris Paton - Honorary Visiting Scientist
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Ashata Dahal
Ashata Dahal - Public Engagement Manager (OUCRU Nepal)/ DPhil candidate (University of Oxford)
Suchita Shrestha
Suchita Shrestha - Head of the Clinical Trials Unit, OUCRU Nepal
Gisela Robles Aguilar
Gisela Robles Aguilar - Global Burden of Disease Researcher
Rachel Hounsell
Rachel Hounsell - Senior Researcher and Teaching Fellow
Proochista Ariana
- MSc IHTM Executive Team
- MSc IHTM Lecturers
- MSc IHTM advisory committee
- MSc MGH Lecturers
- Principal Investigators
- Research Scientists
Proochista Ariana - Associate Professor
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Kevin Marsh
Kevin Marsh - Professor of Tropical Medicine